Compare INSG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INSG | MDXH |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 183.4M |
| IPO Year | 2000 | 2021 |
| Metric | INSG | MDXH |
|---|---|---|
| Price | $9.83 | $3.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $15.33 | $7.67 |
| AVG Volume (30 Days) | ★ 159.6K | 123.5K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $165,876,000.00 | $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | $14.34 | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $6.24 | $1.35 |
| 52 Week High | $18.11 | $5.33 |
| Indicator | INSG | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 44.64 |
| Support Level | $9.16 | $3.45 |
| Resistance Level | $11.14 | $3.80 |
| Average True Range (ATR) | 0.73 | 0.20 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 23.35 | 5.00 |
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.